<DOC>
	<DOCNO>NCT01692652</DOCNO>
	<brief_summary>Meibum lipid modify patient MGD , result tear instability , evaporative dry eye , eyelid inflammation . These change add corneal damage exacerbate ocular symptom , associate constant release inflammatory mediator . To knowledge , study tear cytokine level MGD patient treat topical loteprednol etabonate . The investigator , thus , evaluate inflammatory tear cytokine level correspond clinical outcome analyze efficacy topical loteprednol etabonate moderate severe MGD . The aim research determine concentration inflammatory tear cytokine patient MGD compare change tear cytokine level topical loteprednol etabonate warm compress treatment group warm compress treatment group .</brief_summary>
	<brief_title>Changes Inflammatory Cytokines Tears Moderate Severe MGD Treated With Topical Loteprednol Etabonate</brief_title>
	<detailed_description />
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>( 1 ) stage 3 4 meibomian gland dysfunction 1. history previous ocular intraocular surgery 2. ocular infection , non dry eye ocular inflammation , ocular allergy , autoimmune disease , 3. history intolerance hypersensitivity component study medication , 4. wear contact lens study period , presence current punctal occlusion , 5. pregnancy , lactate woman , child . 6 . Additionally , patient exclude use topical ocular systemic medication could use treatment MGD dry eye , include topical oral antibiotic , topical cyclosporine A , topical oral steroid , topical nonsteroidal antiinflammatory drug , topical ocular allergy medication artificial tear</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>